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ABSTRACT
Which of the available antiplatelet therapies should be
preferred for secondary prevention of recurrent ischemic
stroke has been contentious.
Objective: We applied the Duke Stroke Policy Model
(DSPM) to reconsider this issue, paying particular atten-
tion to the degree of uncertainty in the estimates of their
efﬁcacy. The DSPM is a continuous-time simulation
model of stroke development and outcome.
Methods: We modiﬁed the inputs to reﬂect the cost of the
drugs aspirin (ASA), extended release dipyridamole/aspi-
rin (DP/A) and clopidogrel (CLO), as well as their relative
risk in preventing subsequent ischemic stroke in compar-
ison with placebo (PBO). These relative risks were derived
from published reports from the second European Stroke
Prevention Study (ESPS-2) and Clopidogrel Versus Aspir-
ing in Patients at Risk of Ischemic Events studies. Preci-
sion was addressed by applying bootstrapping to the
above estimates of relative risk. The target population
was 70-year-old men with nondisabling stroke. The out-
come measures were quality-adjusted life-years (QALYs),
costs, and costs per QALY.
Results: Results of Base Case Analysis: In large part
because of its modest drug cost, ASA was cost-effective in
comparison with PBO. DP/A tended to have improved
outcomes, but at increased costs. CLO was dominated in
the base case. Results of sensitivity analysis: ASA and
DP/A cannot be differentiated on a statistical basis alone.
In probabilistic sensitivity analysis, CLO was rarely
preferred.
Conclusions: Either DP/A or ASA appear to be a good
value in comparison with no treatment, but there is no
clear winner between the two. In the absence of a deﬁn-
itive randomized trial, simulation modeling can help clar-
ify the trade-offs between the various antiplatelet agents,
but not beyond the constraints imposed by the impreci-
sion in the estimates that can be obtained from the current
evidence base.
Keywords: antiplatelet, bootstrapping, cost-effectiveness
acceptability curves, cost-effectiveness modeling, second-
ary stroke prevention, simulation analysis.
Introduction
An ischemic stroke is not only costly and potentially
debilitating in and of itself, but also places the
patient at increased risk for subsequent events such
as recurrent ischemic stroke, myocardial infarction
(MI) and premature death. Among the options for
preventing these subsequent events are antiplatelet
agents such as aspirin (ASA), a combination of
extended release dipyridamole/aspirin (DP/A), and
clopidogrel (CLO). The value of speciﬁc antiplatelet
agents for secondary prevention has been conten-
tious [1–3], as has been comparisons among the
antiplatelet agents themselves.
One reason that comparisons among ASA, DP/A,
and CLO have been difﬁcult is the lack of a single
large, deﬁnitive randomized controlled trial that
includes each of these three agents, a placebo con-
trol group (PBO), and a sufﬁciently long follow-up
time to observe their long-term implications in
terms of mortality, quality of life, and health-related
costs. Because it is unrealistic to expect that such a
trial will ever be performed, other approaches are
required. In particular, the technique of simulation
modeling is often used to combine information
across multiple data sources, and thus is of potential
beneﬁt here.
We applied the Duke Stroke Policy Model
(DSPM), a peer-reviewed simulation model of the
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natural history of stroke and the impact of various
prevention strategies [4–6], to the task of compar-
ing the four strategies of secondary stroke pre-
vention listed above (ASA, DP/A, CLO, PBO).
Particular attention was given to assess the preci-
sion of the resulting conclusions: that is, the limits
of certainty regarding this comparison, given the
data that are currently available from the literature.
Methods
Duke Stroke Policy Model
The DSPM follows simulated patients, whether
with a history of cerebrovascular disease or asymp-
tomatic, as they develop the model-relevant health
events of transient ischemic attack (TIA), MI,
ischemic stroke (IS), hemorrhagic stroke (HS), and
death (DT). Because the focus of the current appli-
cation is on secondary prevention after IS, the
asymptomatic and TIA states were dropped, and
only the states MI, IS, HS, and DT are utilized.
In a typical application of the SPM, patients with
a new ischemic stroke are randomly assigned a level
of stroke severity, based on the distribution of
Rankin scores observed in the literature. The
Rankin score is an integer from 1 to 5, with increas-
ing scores indicating greater disability [7]. Here, to
focus on those patients with mild stroke that are
likely to be particularly good candidates for
antiplatelet therapy, all patients were assigned an
initial Rankin score of 1.
Each simulated patient in the SPM generates a
history of model-relevant events. For example, one
patient may die after 754 days, and another may
have a recurrent IS with a Rankin level 3 on day 36,
another recurrent IS with Rankin level 5 on day 76,
and die after 205 days. These patient histories are
generated by randomly sampling from “transition
functions” (i.e., event rates over time) generated
from an analysis of data from the Framingham
Study [8]. Once this history of events is generated,
costs and utilities (i.e., quantitative representations
of health-related quality of life) are attached accord-
ing to health state. In particular, those health states
with a higher level of disability are more costly, and
associated with a lower quality of life, than states
with less disability. Costs were estimated from
Medicare claims data, and utilities were estimated
from a large survey of patients at risk for major
stroke. The principal model outputs for purposes of
this presentation are total medical costs and quality-
adjusted life-years (QALYs). The latter output is
produced by adjusting simulated patient survival
for observed time spent in states of disability.
Details regarding data sources, parameter estimates,
and software implementation and validation are
available in other publications, and also on a Web
site (http://diseasemodels.duhs.duke.edu/).
To apply the DSPM to the question of secondary
prevention using antiplatelet therapy, the following
modiﬁcations were made: 1) the PBO group was
assumed  to  follow  the  natural  history  of  70-
year-olds with the characteristics (e.g., percent
hypertensive) of those patients in the Framingham
population with ﬁrst ischemic stroke; 2) for each
antiplatelet group, the cost per month was increased
by an estimated cost of antiplatelet medications;
and 3) for each antiplatelet group, the risk of sub-
sequent IS was reduced, using a risk ratio that was
estimated from the randomized trials discussed
below. In the base case, this risk ratio was applied to
the event rates for the patient lifetime. In a sensitiv-
ity analysis, efﬁcacy was assumed to persist only for
24 months (i.e., the approximate duration of the
clinical trials).
Parameter Estimates
The most fundamental parameters in this cost-
effectiveness analysis are the risk ratios for subse-
quent IS, in comparison with PBO, associated with
ASA, DP/A, and CLO. To obtain these risk ratios,
we must 1) select the randomized trials to be used in
their estimation; and 2) estimate the risk ratios from
those trials, focusing on patients with TIA or IS.
Regarding the selection of the randomized trials,
as noted previously no sufﬁciently large trial simul-
taneously compared all of ASA, DP/A, CLO, and
PBO. Nevertheless, the second European Stroke
Prevention Study (ESPS-2) [9] included ASA, DP/A,
and PBO, whereas the trial of Clopidogrel Versus
Aspirin in Patients at Risk of Ischemic Events
(CAPRIE) [10] included CLO and ASA. Both stud-
ies were large (ESPS-2 recruited 6602 adults with a
TIA [25%] or IS [75%] within the prior 3 months
and CAPRIE randomized 6431 subjects with IS as
their qualifying condition). Loss to follow up was
similarly low (0.64% for ESPS-2 and 0.22%, for
CAPRIE). It is notable that the two study popula-
tions had only modest differences: subjects in ESPS-
2 were somewhat older on average (66.7 vs.
64.6 years), with a larger proportion of women
(42% vs. 36%), a smaller proportion of individuals
with diabetes mellitus (15% vs. 26%), hypertension
(61% vs. 65%), hypercholesterolemia (23% vs.
38%), or heart failure (8% vs. 10%), and a larger
proportion of individuals with atrial ﬁbrillation
(7% vs. 4%) or current smoking (24% vs. 22%).
Though the ASA doses were different (25 mg twice
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daily for ESPS-2 vs. 325 mg once daily for
CAPRIE), within these ranges dose effects have not
been apparent in meta-analyses [11,12]; further-
more, event rates for the ASA treated subjects were
similar with 6.25 strokes and 1.18 MIs per 100
patient-years for ESPS-2 and 5.65 strokes and 0.85
MIs per 100 patient-years for CAPRIE.
These trials were noticeably larger than the other
studies in the literature on the use of antiplatelet
therapy for stroke prevention; accordingly, rather
than attempting to derive meta-analytically based
estimates of the impact of ASA, DP/A, and CLO
across multiple heterogeneous studies, the present
analysis utilizes ESPS-2 and CAPRIE alone.
Regarding the estimation of risk ratios from those
trials, the DSPM could potentially accommodate the
modiﬁcation of some or all of the Framingham-
based risk ratios associated with new MI (i.e., “tran-
sition from IS to MI”), new HS, recurrent IS, or death
from causes other than MI or stroke. For simplicity,
in our baseline analysis, we assumed that antiplatelet
agents only had an impact on new IS and that their
impact on new HS, MI, and death from causes other
than MI or IS would be minimal; accordingly, these
event rates were unchanged. Equivalently, their risk
ratios, in comparison with PBO, were assumed to be
1. This decision will yield a conservative estimate of
the cost-effectiveness of the antiplatelet agents, by
potentially understating the number of events that
they will prevent. In any case, in sensitivity analysis
we included risk ratio estimates for MI and death
from causes other than stroke or MI as a check on
the robustness of our baseline results.
To estimate the three risk ratios associated with
recurrent IS—that is, for ASA versus PBO, for DP/A
versus PBO, and for CLO versus PBO—we began
with information from the ESPS-2 trial. This trial
provided a 2 ¥ 2 table that compares the outcomes
for ASA versus PBO (i.e., the two dimensions of the
table were group [ASA, PBO] and outcome [IS, no
IS]). The point estimate for the relative risk of ASA
versus PBO can be directly estimated from the ele-
ments of this 2 ¥ 2 table; that is, from the propor-
tion of ASA patients experiencing a recurrent stroke
divided by similar proportion among patients
receiving PBO. The precision associated with this
point estimate can be obtained by 1) within the PBO
group, sampling from a binomial distribution
having as its parameters the number of patients in
the PBO group and the proportion of PBO patients
experiencing a recurrent IS during the ESPS-2
follow-up period; 2) within the ASA group, sam-
pling from a binomial distribution having as its
parameters the number of patients in the ASA group
and the proportion of ASA patients experiencing a
recurrent IS during the ESPS-2 follow-up period;
and 3) from the 2 ¥ 2 table obtained from this
“bootstrapped” resampling process, calculating the
new risk ratio. Repeating this process multiple times
provides an estimate of the precision associated
with the original point estimate. An identical proc-
ess was followed, using data from the ESPS-2 trial,
to obtain estimates of the risk ratio associated with
DP/A versus PBO.
To obtain estimates of the risk ratio associated
with CLO versus PBO, we ﬁrst used data from the
CAPRIE trial to estimate the risk ratio associated
with CLO versus ASA. Then, this estimate was mul-
tiplied by the estimate of the risk ratio for ASA ver-
sus PBO obtained from the ESPS-2 study. The
precision of both the risk ratio for CLO versus ASA
and the risk ratio for ASA versus PBO were esti-
mated using resampling. In particular, for each iter-
ation of the resampling process we used binomial
distributions (as stated previously) to generate two
risk ratios (CLO vs. ASA, ASA vs. PBO), which
were then multiplied together.
Within the ESPS-2 trial, the placebo group had
250 strokes in 1649 patients at risk, whereas the
ASA group (50-mg dose) had 206 strokes in 1649
patients at risk, the estimated risk ratio versus PBO
being 0.82. Similarly, the DP/A group had 157
strokes in 1650 patients at risk, the estimated risk
ratio versus PBO being 0.63. Within the CAPRIE
trial, the CLO group had 315 strokes in 3233
patients at risk, whereas the ASA group (325-mg
dose)  had  338  strokes  in  3198  patients  at  risk.
The risk ratio of CLO versus ASA thus was 0.92,
and the risk ratio of CLO versus PBO was
(0.92)(0.82) = 0.76.
Baseline costs were approximated based on
prices from a wholesale pharmacy Web site [13]; the
monthly costs associated with ASA, DP/A, and
CLO were set to be $1, $120, and $120, respec-
tively. For sensitivity analysis, alternative estimates
were obtained from the Federal Supply Schedule
[14]; for ASA, DP/A, and CLO these were $0.21,
$48, and $61, respectively.
Analysis
To obtain an initial point estimates for the cost-
effectiveness analysis (CEA), we ran the SPM for
10,000 simulated patients for each of the ASA, DP/
A, CLO, and PBO groups, changing the risk ratios
for recurrent IS as described above and thus gener-
ating different estimates of lifetime survival, lifetime
quality-adjusted survival, and lifetime health-related
costs for each group. It was previously determined
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that 10,000 simulated patients is computationally
tractable and also yields sufﬁcient precision, in com-
parison with the Monte Carlo variability in the
simulation, for estimating outcomes given any par-
ticular set of the SPM’s inputs. To provide a visual
sense of the relationship between estimated cost and
effectiveness for each treatment and the variability
in these estimates induced by variability of inputs,
the results of the 100 replicates are plotted on the
coordinate axes of cost versus effectiveness.
Any two groups from the above simulation can
be compared in the traditional manner using the
incremental cost-effectiveness ratio (ICER) that
divides the difference in cost between the strategies
by the difference in QALYs. To accommodate the
presence of more than two groups, we ﬁrst ordered
the results by increasing QALYs. The strategy yield-
ing the fewest QALYs was the initial standard for
comparison. This was paired with the strategy with
the next-fewest QALYs. This latter strategy was
preferred if the improvement in outcomes came at a
reasonable cost; for example, if the ICER was no
more than $50,000 per QALY. The benchmark
ICER value was varied from $10,000 through
$100,000 per QALY. The “winning” strategy from
this initial pair was then compared with the strategy
with the next-higher QALYs, and then the winner
from this comparison was compared with the strat-
egy having the highest QALYs. Thus, each replica-
tion of the cost-effectiveness analysis (CEA)
generated a single optimal strategy.
To assess the impact of sampling variability
associated with the ESPS-2 and CAPRIE trials, the
above procedure was repeated 99 times (100 repli-
cations total), with 10,000 simulated patients per
strategy per replication, and the parameter esti-
mates obtained from resampling from the original
data from the trials, as described above. We then
counted the number of times, out of 100, that each
strategy was judged to be optimal. This procedure,
termed cost-effectiveness acceptability analysis, is
presented graphically as a plot of the percent of sim-
ulated trials that each treatment would be the “win-
ner” for different threshold values of benchmark
(acceptable) ICER [15].
To examine the robustness of the base case anal-
ysis, in addition to the “probabilistic sensitivity
analysis” above, we performed several conventional
sensitivity analyses. First, we applied risk ratio esti-
mates for ASA from two published meta-analyses
[11,12]. Second, medication costs were changed to
Federal Supply Schedule prices. Third, treatment
efﬁcacy was presumed to persist only for 24
months. Finally, risk ratios for MI based on clinical
trial data were used.
Results
Base case results for each treatment are shown in
Table 1, based on the means for 100 runs of 10,000
patients each. The point estimates for mean incre-
mental cost effectiveness indicates that CLO and
DP/A have reasonable ICERs, though DP/A is “pre-
ferred” by extended dominance. Figure 1 presents
the results of a sample of 100 runs of the cost-
effectiveness analysis. Each replication produced
one data point per strategy. Because its inputs were
identical except for the random seed used to per-
form the simulation, the variation in the results for
the usual care strategy illustrates the relatively small
imprecision induced by basing the simulation on
the computationally tractable number of 10,000
patients per replicate. The much greater variation in
the results for the antiplatelet agents reﬂects the
imprecision in the relative risk estimates attributa-
ble to the sampling variation in the two randomized
trials.
Figure 1 illustrates four points. First, in compar-
ison with PBO, ASA leads to modest improvements
in outcome at minimal cost. Put in visual terms, the
data points for ASA tend to be above (i.e., more
QALYs) and to the right (i.e., more cost) of those
for PBO, but more above than to the right. Using
traditional cost-effectiveness benchmarks (e.g.,
$50,000 per QALY), ASA tends to be cost-effective
in comparison with PBO; that is, the extra beneﬁts
associated with ASA are usually worth the extra
cost (mean ICER = $1725, Table 1).
Dipyridamole/aspirin leads to additional im-
provements in outcome compared with ASA, at
Table 1 Base case results, 100 runs of 10,000 patients
Treatment Cost ($) QALYs
Incremental
cost ($)
Incremental
QALYs
Incremental cost-effectiveness
ratio ($/QALYs)
PBO 48,405 3.54
ASA 48,681 3.70 276 0.16 1,725
CLO 52,721 3.77 4,040 0.07 57,714
DP/A 53,004 3.93 283 0.16 1,769
ASA, aspirin; DP/A, combination sustained-released dipyridamole/aspirin; PBO, placebo; QALYs, quality-adjusted life-years.
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additional cost. The DP/A data points tend to be
above and to the right of those for ASA, but fur-
ther to the right than the comparison between ASA
and PBO. Both the DP/A and ASA data points tend
to fall near two parallel lines. This is due to the
phenomenon that as survival increases, so does
lifetime medical cost. The DP/A line is shifted to
the right because of the extra monthly cost of the
drug.
Third, the comparison between ASA and DP/A is
not deﬁnitive. For some of the replications of the
simulations, ASA results in slightly more QALYs
than DP/A. More often, DP/A results in better qual-
ity-adjusted life expectancy, but the difference is suf-
ﬁciently modest that small changes in QALYs lead
to large changes in the ICER, sometimes leading to
the conclusion that the additional beneﬁts of DP/A
are worth the cost, and sometimes not.
Fourth, the results for CLO are much more sim-
ilar to those of DP/A than those of ASA. Although
considerable overlap in the data points is apparent,
the results for CLO are, in general, shifted some-
what below and to the left of those for DP/A, in
large part because the point estimate for the efﬁcacy
of CLO is somewhat lower than that of DP/A.
Figure 2 summarizes the results of the 100 sets of
comparisons (i.e., one set of comparisons per repli-
cation of the simulations), using cost-effectiveness
acceptability curves. Only in exceptional cases are
PBO or CLO the preferred strategy and CLO is not
optimal for a plurality of simulations, at any bench-
mark ICER. The choice of optimal strategy usually
involves a comparison between ASA and DP/A, the
question being whether the beneﬁts of the latter are
worth the increased drug-related costs. The lower
the ICER benchmark for declaring a more effective
strategy to be cost-effective, the more likely it is that
DP/A will be preferred. Nevertheless, the com-
parison is not deﬁnitive; that is, at any reasonable
ICER benchmark both DP/A, and ASA are pre-
ferred in more than a nontrivial number of the rep-
lications, and thus the implications of these two
strategies cannot be differentiated on a statistical
basis alone.
To examine the robustness of the base case anal-
ysis, we performed several sensitivity analyses
(Table 2). Applying risk ratio estimates for ASA
from two published meta-analyses [11,12] had no
substantive impact. Reducing medication cost esti-
mates to those from the Federal Supply Schedule
Figure 1 Cost versus QALYs for each strategy, 100 replications of 10,000 patients in each treatment arm.
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enhanced the base case results; this particularly
made DP/A more cost effective and CLO less.
Reducing the assumed efﬁcacy of treatment to the
approximate period of the trial took the mean ICER
for the ASA alternatives out of the clearly cost-
effective range. Including risk ratios for MI based
on clinical trial data led to substantively similar
ICER results as those for the base case.
Discussion
These simulations consistently supported the use of
antiplatelet agents in comparison with placebo for
secondary prevention of recurrent stroke among
patients with a mild ﬁrst ischemic stroke. In partic-
ular, with the drug-related costs of ASA being so
low, even a relatively modest beneﬁt in reducing the
risk of recurrent strokes will be judged to be cost-
effective in comparison with PBO. Less obvious is
the choice between ASA and the more expensive
antiplatelet agents. The more one is willing to pay in
exchange for improved outcomes, the more likely it
is that DP/A will be preferred to ASA. CLO was sel-
dom the preferred strategy, in large part because the
point estimate of its efﬁcacy was less than the point
estimate of the efﬁcacy of DP/A.
Figure 2 Cost-effectiveness acceptability
curves: Percentage of 100 replications for
which the strategy is optimal versus the
ICER benchmark.
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Table 2 Sensitivity analyses
Treatment Cost ($) QALYs
Incremental
cost ($)
Incremental
QALYs
Incremental cost-effectiveness
ratio ($/QALYs)
Ia. Sensitivity analysis: risk ratio for aspirin based on [11]
PBO 48,405 3.54
ASA 48,758 3.75 353 0.21 1,681
CLO 52,721 3.77 3,963 0.02 198,150
DP/A 53,004 3.93 283 0.16 1,769
Ib. Sensitivity analysis: risk ratio for aspirin based on [12]
PBO 48,405 3.54
ASA 48,660 3.69 255 0.15 1,700
CLO 52,721 3.77 4,061 0.08 50,762
DP/A 53,004 3.93 283 0.16 1,769
II. Cost based on [14]
PBO 48,405 3.54
ASA 48,655 3.70 250 0.16 1,562
DP/A 50,569 3.93 1,914 0.23 8,321
CLO 50,760 3.77 191 -0.16 Dominated
III. Efﬁcacy limited to 24 months
PBO 48,405 3.54
ASA 48,480 3.56 75 0.02 3,750
CLO 52,356 3.56 3,876 0.00 Dominated
DP/A 52,399 3.58 3,919 0.02 195,950
IV. Accounting for impact of treatment on MI
PBO 48,405 3.54
ASA 48,692 3.73 287 0.19 1,511
CLO 52,865 3.82 4,173 0.09 46,367
DP/A 53,115 3.97 250 0.15 1,667
Dominated, strictly dominated (QALYs lower than less costly option).
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One goal of the simulations was to assess the
degree of precision and conﬁdence that can be real-
istically associated with comparisons between ASA,
DP/A, CLO and PBO. Although the above conclu-
sions held in general, the results were not sufﬁ-
ciently robust to select between DP/A and ASA
based on statistical considerations alone. Also, it
should be noted that any direct comparisons
between DP/A and CLO critically depend on the
validity of the approach used to estimate the point
estimate and precision of the risk ratio for CLO ver-
sus PBO (to be discussed later in this article).
A number of limitations merit attention. First, the
design and study populations of the ESPS-2 and
CAPRIE trials were not identical; for example, as il-
lustrated in the (albeit not dramatic) differences be-
tween the absolute event rates observed in their ASA
groups. As is typical in information synthesis appli-
cations such as meta-analysis and decision mode-
ling, we chose to use risk ratios, which tend to be
more robust to differences in baseline rates than
absolute rates or their difference scores.
Second, we conservatively estimated that
antiplatelet agents reduced the risk of ischemic
stroke but not MI or death from causes other than
stroke or MI. Although some investigators tend to
only include treatment effects that are either the
point of analysis or are statistically signiﬁcant, oth-
ers choose to include all plausible treatment effects
and, so to speak, let the simulated chips fall where
they may. It is reasonable to posit that any agent
that reduces stroke risk might reduce the risk of MI,
we performed a separate analysis including trial
data on MI risk. As shown, overall conclusions are
unchanged.
Third, although the ASA doses used in the two
trials were different, a key assumption is that the
ASA arms of the two trials are comparable for pur-
poses of calculating risk ratios. In support of this
assumption is the observation in the APTC analyses
[11] as well as the Matchar et al. [12] analysis
involving a meta-regression that efﬁcacy is not sub-
stantively effected by doses in the range used in the
two trials.
Fourth, complication rates were assumed to be
similar for all antiplatelet agents. Although the
major complications are not substantively different,
the rate of complications requiring drug discontin-
uation is different. The effect of complications on
diminished adherence is accounted for here in that
the source trials analyzed their data by “intention to
treat.” This issue is a concern to the extent that
medication adherence is expected to be different
from trial experience.
Fifth, the natural transition estimates used in the
model were based on cohort data in which some
individuals were likely taking an antiplatelet agent.
The hazard functions underlying the SPM provide
natural history projections, which apply equally to
each treatment arm; any error introduced by failing
to account for ambient use of antiplatelet therapy
is substantially diminished in the incremental
calculations.
On the point of the validity of the risk ratio esti-
mates, the mechanics of the SPM require, for each
intervention group, the relative risks of that group
versus placebo. The reason is that the PBO group is
equated to the usual care group on which the Fram-
ingham-based event rates are derived, and thus that
the risk ratios that modify these event rates must be
deﬁned relative to this “default.” Making this trans-
formation for the ASA and DP/A groups was
straightforward, because direct evidence regarding
these risk ratios was available from the ESPS-2 trial.
Also straightforward was the derivation of the point
estimate for the relative risk of CLO versus PBO as
a product of the risk ratio for CLO versus ASA
times the risk ratio of ASA versus PBO.
The more difﬁcult methodological question
involves how best to determine the precision asso-
ciated with the risk ratio comparing CLO with
PBO. The most precision (smallest conﬁdence inter-
val) would be obtained by multiplying the resam-
pling-based estimate of the risk ratio for CLO
versus ASA by a constant—that is, for each iteration
of the resampling, to have the estimate of the risk
ratio of CLO versus ASA reﬂect the sampling error
in the CAPRIE trial, but not to have the estimate of
the risk ratio of ASA versus PBO reﬂect the sam-
pling error in the ESPS-2. The least precision (larg-
est conﬁdence interval) is obtained by the procedure
reported in the results. Although this procedure
does appropriately reﬂect the additional uncertainty
in deriving comparisons between CLO and PBO
using data from the CAPRIE trial, in some sense it
may fail to adequately consider that this trial was
designed with another comparison in mind; namely,
between CLO and ASA. In any event, were the
former procedure of multiplying the risk ratio of
CLO versus ASA by a ﬁxed constant to be applied,
then 1) the variability of the risk ratio for CLO
versus PBO is similar to that of DP/A versus PBO; 2)
in comparison with the DP/A group, most of the
points from the CLO group remain below and to
the left, reﬂecting less efﬁcacy for CLO; and 3) it
remains the case that CLO is seldom judged as the
optimal strategy. Thus, the overall conclusions
remain unchanged. A mathematical derivation of
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the conﬁdence interval for the risk ratio of CLO ver-
sus PBO is provided in the Appendix.
As a ﬁnal point of methodology, it might be
noted that the cost acceptability curve presentation
in Figure 2 is typically used for a comparison be-
tween two strategies. Figure 2 illustrates that this
idea can be straightforwardly extended to compar-
isons involving more strategies than just two.
As an exercise in methodology, it is important to
compare the approach taken here with previous
cost-effectiveness analyses of antiplatelet agents for
secondary stroke prevention. Sarasin and colleagues
[16] used a discrete time Markov model. Our report
complements this work by showing how the uncer-
tainty in the input estimates translates explicitly
into uncertainty in the estimate of incremental cost-
effectiveness. Shah and Gondek [17] performed an
analysis with a 2-year horizon, focusing on cost per
stroke averted. Schleinitz et al. [18] consider ASA
compared with CLO in an analysis based only on
the CAPRIE data and, in that context, conclude that
CLO is cost-effective. Our analysis illustrates the
point that such a conclusion depends on limiting
the universe of plausible alternatives under
consideration.
In conclusion, simulation modeling supports the
use of antiplatelet agents over placebo for second-
ary prevention of recurrent stroke among patients
with a mild ﬁrst ischemic stroke. ASA is consistently
superior to PBO. The choice between ASA and DP/
A is less obvious, but the more the decision-maker is
willing to pay for improved outcomes the more
likely it is that DP/A will be preferred. CLO was sel-
dom judged to be the optimal strategy, in large part
because the point estimate of its efﬁcacy was less
than the point estimate of the efﬁcacy of DP/A.
Although the simulations consistently support the
above general conclusions, the results were not
sufﬁciently robust to select between DP/A and ASA
based on statistical considerations alone. Indeed,
this analysis reinforces the notion that sometimes a
contentious issue is, effectively, a toss-up [19].
Source of ﬁnancial support: The Stroke Policy Model was
developed with support from the Agency for Health Care
Research, Quality (1 R03 HS11746-01). The current
application was developed while Drs Matchar, Samsa
served as consultants to Boehringer Ingelheim.
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Appendix
First consider the relative risk of ASA versus PBO
derived from the 2 ¥ 2 table generated by the ESPS-
2 trial.
The risk of outcome for ASA is A/(A + B) = 206/
1649 = 12.5%. The risk of outcome for PBO is C/
(C + D) = 250/1649 = 15.2%. The risk ratio (i.e.,
RR) for ASA versus PBO is 0.125/0.152 = 0.824.
Recognizing that the results of the ASA and PBO
groups are statistically independent, and applying
Taylor’s formula to the logarithm of the RR, the fol-
lowing formula for an approximate 95% conﬁ-
dence interval is easily derived:
IS during follow-up No IS during follow-up
ASA A = 206 B = 1443
PBO C = 250 D = 1339
RR = exp {log RR ± 1.96 (1/A + 1/C - 1/B - 1/D)1/2]
The resulting conﬁdence intervals are presented
in the ﬁrst three rows of the table below. In absolute
terms, the conﬁdence interval for the RR of CLO
versus ASA is no smaller than the other risk ratios,
despite being estimated from a study with twice the
sample size, the main reason being the impact of the
RR on the width of the conﬁdence interval.
To derive a conﬁdence interval for the RR for
CLO versus PBO, one approach is to treat the com-
parison between ASA and PBO as a random varia-
ble. If so, because the ESPS2 and CAPRIE trials are
independent, the formula becomes:
RR =  exp {log RR ±  1.96  ([1/A +  1/C -  1/B -
1/D] + [1/A* + 1/C* + 1/B* + 1/D*])1/2], where the
asterisks denote the elements of the 2 ¥ 2 table from
the second study (row 4).
Alternatively, if the RR for ASA versus PBO is a
ﬁxed constant, then it sufﬁces to take the RR for
CLO versus ASA from row 3 above, and to multiply
the endpoints of that conﬁdence interval by 0.824
(row 5).
Comparison Point estimate 95% conﬁdence interval
ASA vs. PBO 0.824 0.677–1.003
DP/A vs. PBO 0.628 0.508–0.775
CLO vs. ASA 0.922 0.785–1.083
CLO vs. PBO 1 0.760 0.589–0.979
CLO vs. PBO 2 0.760 0.647–0.892
